<DOC>
	<DOCNO>NCT00984932</DOCNO>
	<brief_summary>Although aetiology SSc-PAH remain elusive , vascular dysfunction seem initial event statin vasculoprotective effect might value treatment armamentarium PAH relate SSc . The aim ass efficacy rosuvastatin ameliorate vascular dysfunction management SSc-related PAH .</brief_summary>
	<brief_title>Effect Rosuvastatin Systemic Sclerosis-related Pulmonary Hypertension</brief_title>
	<detailed_description>Background : Pulmonary arterial hypertension ( PAH ) acknowledge devastate complication systemic sclerosis ( SSc ) ; difficult manage poor prognosis . Although aetiology SSc-PAH remain elusive , vascular dysfunction seem initial event . Statins , pleotropic effect might value treatment armamentarium PAH relate SSc . Objectives : The aim ass efficacy rosuvastatin ameliorate vascular dysfunction management SSc-related PAH . Methods : Forty SSc patient fulfil ACR criterion classification SSc diagnosis PAH recruit . All SSc patient underwent transthoracic echocardiography six minute walk test ( SMWT ) . Patients randomize 2 group ; first group ( n = 23 ) assign receive 40mg rosuvastatin second group ( n = 23 ) receive placebo 6 month . The level endothelial dysfunction inflammatory marker assay baseline 6 month therapy . Outcome measure assess include exercise capacity ( SMWT ) , MPAP , WHO functional class change , tolerability safety .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>New York Heart Association ( NYHA ) class III A mean pulmonary artery pressure ( mPAP ) &gt; 30mmHg rest Smoking Diabetes mellitus Hypercholesterolemia Hypertension Cardiac insufficiency Coexisting hepatic renal disease Use drug know interact statin . Patients severe interstitial lung fibrosis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>systemic sclerosis</keyword>
	<keyword>pulmonary hypertension</keyword>
	<keyword>rosuvastatin</keyword>
</DOC>